MedWatch

Analyst: Increasing inflation will have multimillion-dollar impact on Novo Nordisk

Increasing cost pressure will slice 10 percent off Novo Nordisk’s profit in 2023, says analyst institution Intron Health.

Photo: Novo Nordisk / PR

Novo Nordisk will take a blow from rising energy costs and an increasing cost pressure due to inflation, according to an analysis from UK-based global healthcare equity research firm Intron heath, which Danish business daily Børsen has seen.

Increasing cost pressure could reduce Novo Nordisk’s profits by nearly 10 percent in 2023, according to Naresh Chouhan, an analyst at Intron Health.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs